Zimmer Biomet (NYSE:ZBH) Raised to “Buy” at Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Other research analysts have also issued reports about the company. Citizens Jmp lowered their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. UBS Group reissued a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a report on Wednesday, February 11th. William Blair initiated coverage on Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. Finally, Leerink Partners initiated coverage on Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $102.80.

Zimmer Biomet Stock Performance

ZBH stock opened at $82.24 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The stock has a market capitalization of $15.91 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 1.90 and a beta of 0.48. Zimmer Biomet has a 1 year low of $79.83 and a 1 year high of $108.29. The stock’s fifty day moving average is $91.56 and its two-hundred day moving average is $92.31.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period last year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts predict that Zimmer Biomet will post 8.47 EPS for the current year.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rakuten Investment Management Inc. acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $37,307,000. Sector Gamma AS boosted its position in Zimmer Biomet by 28.0% during the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after acquiring an additional 24,847 shares during the period. SG Americas Securities LLC boosted its position in Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after acquiring an additional 13,812 shares during the period. Border to Coast Pensions Partnership Ltd boosted its position in Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after acquiring an additional 22,104 shares during the period. Finally, National Pension Service boosted its position in Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after acquiring an additional 16,928 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.